Every 424B that Lionsgate Studios Corp. (LION) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LION and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LION filings page.
New Lionsgate (LION) is registering 157,869 shares of common stock to cover outstanding New Lionsgate Options and New Lionsgate SARs issued under the New Lionsgate 2025 Plan. These instruments converted from LGEC awards as part of the separation transactions that created New Lionsgate.
Proceeds from exercises of the covered Options and SARs are expected to be used for general corporate purposes. The prospectus date is June 5, 2026, and New Lionsgate common stock closed at $13.40 per share on June 5, 2026 as reported on the NYSE.
Registration of 208,122 Common Shares — This Prospectus Supplement registers 208,122 common shares related to exercises of options and stock appreciation rights issued under the Lionsgate Studios Corp. 2025 Performance Incentive Plan. It supplements the Prospectus dated August 5, 2025 and attaches a Form 8-K filed April 15, 2026.
The Form 8-K discloses a First Amendment to CEO Jon Feltheimer’s employment agreement: the term is extended through July 31, 2031, and he was granted a 4,500,000-option award (exercise price $11.07) and 666,667 RSUs in three performance-and-service vesting tranches with stock-price hurdles of $17.50, $20.00 and $22.50 (each measured by a 20-day average) and five-year performance periods. The supplement notes the last reported NYSE sale price was $11.09 per share on April 14, 2026.
Lionsgate Studios Corp. registers 208,122 Common Shares under the 2025 Performance Incentive Plan to cover exercises of stock options and SARs held by former employees and their transferees. Proceeds from exercises will be used for general corporate purposes.
This Prospectus Supplement, dated March 18, 2026, supplements the Prospectus and attaches a Form 8-K filed on March 18, 2026 that reports final voting results from the Company’s Annual Meeting held March 17, 2026. The Common Shares trade on the NYSE under the symbol LION; the last reported sale price on March 17, 2026 was $9.68 per share.
Lionsgate Studios Corp. filed a prospectus supplement covering the exercise of stock options and stock appreciation rights to acquire up to 208,122 common shares held by certain former employees, with any cash proceeds to be used for general corporate purposes. The supplement also incorporates the company’s latest Quarterly Report and recent Current Reports.
For the quarter ended December 31, 2025, Lionsgate generated revenues of $724.3 million and operating income of $36.0 million, but reported a net loss attributable to shareholders of $46.2 million, or $0.16 per basic and diluted share. For the nine‑month period, revenue was $1.73 billion with a net loss of $268.5 million, or $0.95 per share, reflecting high interest expense, content amortization and restructuring costs.
At December 31, 2025, the company reported total assets of $5.24 billion, total liabilities of $6.38 billion and a shareholders’ equity deficit of $1.28 billion. Debt, excluding film‑related obligations, totaled $1.96 billion, alongside $2.06 billion of film‑related obligations, while cash and cash equivalents were $182.4 million and operating activities used $321.7 million of cash from continuing operations over nine months.